Vaccines

California To Hold Its First Large In-Person Medical Convention at the Los Angeles Convention Center on July 8-11, 2021

Retrieved on: 
Tuesday, June 29, 2021

Attendees must be vaccinated or have a proof of negative COVID19 tests.

Key Points: 
  • Attendees must be vaccinated or have a proof of negative COVID19 tests.
  • Face coverings are optional for fully vaccinated attendees with a proof of vaccination record but mandatory for unvaccinated or partially vaccinated attendees.
  • "We were the first medical association to shut-down the convention last year and announce the pandemic.
  • Now, we are the first to hold an in-person and virtual (optional) convention in the state of California after its reopening", said the executive director of SBMT, Dr. Vicky Yamamoto.

Government of Canada funds new project to encourage vaccine uptake in Canada

Retrieved on: 
Thursday, June 24, 2021

The Government of Canada is working closely with experts, provinces and territories, and other partners to encourage vaccine confidence and better understand what barriers people may face to getting vaccinated.

Key Points: 
  • The Government of Canada is working closely with experts, provinces and territories, and other partners to encourage vaccine confidence and better understand what barriers people may face to getting vaccinated.
  • The Immunization Partnership Fund isone tool to help people in Canada make informed vaccine choices through community mobilization and public outreach.
  • The Immunization Partnership Fund (IPF) supports projects that improve access to vaccines and encourage vaccine acceptance and uptake.
  • In 2020, as a response to Canada's COVID-19 vaccination efforts and building on the early momentum of the IPF, the Government of Canada invested an additional $64 million for projects to support vaccine uptake in Canada.

Early results from a national study confirm antibody levels are stronger after receiving two doses

Retrieved on: 
Wednesday, June 23, 2021

CanPath is a national population health research platform that follows the health of 330,000 volunteer Canadians (or 1% of the population).

Key Points: 
  • CanPath is a national population health research platform that follows the health of 330,000 volunteer Canadians (or 1% of the population).
  • Early results from this study show a lag in the development of antibodies after a single vaccine dose.
  • The study detected high levels of antibodies in participants with two doses of an mRNA vaccine, with levels almost twice as high as those after the first dose.
  • The Canadian Partnership for Tomorrows Health (CanPath) is Canadas largest population health study and a national platform for health research.

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine

Retrieved on: 
Tuesday, June 22, 2021

The first clinical trial of a seasonal mRNA flu vaccine candidate is an exciting milestone in our quest for the next generation of influenza vaccines.

Key Points: 
  • The first clinical trial of a seasonal mRNA flu vaccine candidate is an exciting milestone in our quest for the next generation of influenza vaccines.
  • We are pleased to have this second mRNA vaccine program underway with our partner Sanofi Pasteur, said Ronald Renaud, chief executive officer, Translate Bio.
  • We look forward to evaluating the potential of these mRNA influenza vaccine candidates in this Phase 1 clinical trial.
  • Sanofi and Translate Bio have developed and will evaluate two formulations of the vaccine (MRT5400 and MRT5401) in the Phase 1 influenza mRNA vaccine clinical trial.

Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine - The Pfizer-BioNTech

Retrieved on: 
Monday, June 21, 2021

The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.

Key Points: 
  • The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.
  • According to Yale Medicine[2], they said that: (Pfizers vaccine has a) 95% efficacy in preventing COVID-19 in those without prior infection.
  • While the efficacy against infection varied between the two studies, both also showed the vaccine provides strong protection.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology

Retrieved on: 
Monday, June 21, 2021

A request for a Pre-Investigator New Drug meeting for the COVID-19 treatment will be submitted to the FDA in the near term.

Key Points: 
  • A request for a Pre-Investigator New Drug meeting for the COVID-19 treatment will be submitted to the FDA in the near term.
  • In addition, all pandemic influenza viruses since 1918 have a similar region as that targeted by this technology.
  • Dr. Mark Dybul, a prominent expert in HIV and Executive Vice Chairperson of the Board of Enochian BioSciences, said, The current COVID-19 variants are concerning.
  • Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy.

Worldwide Dengue Vaccine Industry to 2025 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021

The publisher has been monitoring the dengue vaccine market and it is poised to grow by $132.90 million during 2021-2025, progressing at a CAGR of about 18% during the forecast period.

Key Points: 
  • The publisher has been monitoring the dengue vaccine market and it is poised to grow by $132.90 million during 2021-2025, progressing at a CAGR of about 18% during the forecast period.
  • This report on the dengue vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The dengue vaccine market analysis includes the end-user segment and geographic landscape.
  • This study identifies the initiatives for dengue vaccine research and dengue immunization programs as one of the prime reasons driving the dengue vaccine market growth during the next few years.

More than 70% of PhosAgro's Workforce Has Developed Immunity to COVID-19

Retrieved on: 
Tuesday, June 22, 2021

As of today, 9,032 PhosAgro employees have received at least one vaccine dose, while 8,205 staff members have received both doses.

Key Points: 
  • As of today, 9,032 PhosAgro employees have received at least one vaccine dose, while 8,205 staff members have received both doses.
  • The development of herd immunity is one of the key factors for ensuring the health of employees and the uninterrupted operation of PhosAgro's enterprises.
  • Expert virologists, infectious-disease specialists and vaccine developers have been invited to speak with the workforce.
  • Since 1 June 2016, the Company's GDRs have been included in the MSCI Russia and MSCI Emerging Markets indexes.

More than 70% of PhosAgro's Workforce Has Developed Immunity to COVID-19

Retrieved on: 
Tuesday, June 22, 2021

As of today, 9,032 PhosAgro employees have received at least one vaccine dose, while 8,205 staff members have received both doses.

Key Points: 
  • As of today, 9,032 PhosAgro employees have received at least one vaccine dose, while 8,205 staff members have received both doses.
  • The development of herd immunity is one of the key factors for ensuring the health of employees and the uninterrupted operation of PhosAgro's enterprises.
  • Expert virologists, infectious-disease specialists and vaccine developers have been invited to speak with the workforce.
  • Since 1 June 2016, the Company's GDRs have been included in the MSCI Russia and MSCI Emerging Markets indexes.

CaroGen Partners with BioCentriq™ for Clinical Production of its Novel Immunotherapy CARG-201

Retrieved on: 
Tuesday, June 22, 2021

BioCentriq is a New Jersey based full-service concept-to-clinic contract development manufacturing organization (CDMO) with a mission to support innovative companies reach clinical success.

Key Points: 
  • BioCentriq is a New Jersey based full-service concept-to-clinic contract development manufacturing organization (CDMO) with a mission to support innovative companies reach clinical success.
  • CaroGen is a private biotechnology company with a patented and transformative novel immunotherapy and vaccine platform called AVIDIO, or Artificial Virus for Infectious Diseases and Immuno-Oncology.
  • The AVIDIO platform technology was licensed from Yale University for worldwide use by CaroGen for both prophylactic and therapeutic vaccine applications.
  • CaroGen has completed preclinical proof-of-concept in HBV animal models and selected a clinical candidate, CARG-201.